ligand pharmaceuticals biopharmaceutical company located san diego founded progenix inc company went public initially focused developing drugs period turbulence early culminated ceo ejected shareholders provoked change focus acquisition existing drugs forming partnerships develop furthercitation needed company subject multiple regulatory negative shortsseller class action lawsuits amid allegations securities ceo listed among top five highest paid ceos san ligand pharmaceutical develops acquires royaltygenerating assets comprising numerous technologies therapies drugs receives royalties include kyprolis promacta melphalan ligand pharmaceuticals partnered approximately pharmaceutical companies include captisol captisol ligand indication chemically modified clathrate compound cyclodextrin class designed improve solubility stability bioavailability dosing active pharmaceutical ligand pharmaceuticals founded progenix inc brook byers went public late first ceo howard birndorf succeeded david robinson focused developing drugs based orphan nuclear september company delisted nasdaq following accounting irregularities resulted late month securities exchange commission companys financial reporting characterized questionable resulted lengthy scandal according san diego october company well board directors certain officers named defendants shareholder derivative lawsuit alleging breach fiduciary ligand artificially inflated revenue engaging channel stuffing june ligand agreed pay million settle securities classaction lawsuit well related state federal shareholder derivative lawsuits alleged company engaged accounting addition accounting irregularities company reported profits despite drugs company developed approved dissident shareholders including dan loeb forced robinson outcitation needed replaced ceo henry f blissenbach sold companys commercial operations cut workforcecitation needed january john higgins former investment banker brought ceo changed companys strategy one acquiring candidate drugs forming partnerships develop late company used capital acquire companies including neurogen pharmacopeia biotechnology metabasis therapeutics cydex pharmaceuticals ceo higgins stated result purchases portfolio new drug candidates partnerships pharmaceutical companies november shareholder foundation filed class action lawsuit ligand alleging company engaged securities fraud making false misleading statements overstating value assets misclassifying debt failing maintain control separate classaction lawsuit filed month named ligand ceo john higgins cfo matthew korenberg alleged companys wrongful acts omissions led precipitous decline market value companys stock companys investors suffered significant losses december ligand named defendant multiple securities class action lawsuits alleging company engaged securities fraud making false misleading statements financial condition ability control july ligand sued investors including citadel billion alleging company unfairly modified agreements investors never filed amendment us securities exchange june emmanuel lemelson shorting ligand stock published pages reports criticized company fraud alleged company commentary caused million drop companys market capitalization profit million lemelson ligand executives former high rankingsec lawyer brad bondi congressmen duncan hunter subsequently lobbied us securities exchange commission charge according company emails trial testimony ligand ceo john higgins wanted lemelson silenced september sec sued lemelson alleged manipulative scheme defraud investors november federal jury rejected allegations mixed cleared lemelson commentary ligand reports find misstatements including different company viking lemelson subsequently fined httpsenwikipediaorgwikiligandpharmaceuticals